BLLN
BillionToOne, Inc.
$80.83
-2.31
(-2.78%)
| Exchange: | |
| Market Cap: | 3.699B |
| Shares Outstanding: | 44.72M |
About The Company
| Sector: | Healthcare | |||||
| Industry: | Medical – Diagnostics & Research | |||||
| CEO: | Oguzhan Atay | |||||
| Full Time Employees: | 620 | |||||
| Address: |
|
|||||
| Website: | https://www.billiontoone.com |
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a test that provides longitudinal determination of cancer burden through methylation assessment. The company was incorporated in 2016 and is headquartered in Menlo Park, California.
Click to read more…
Revenue Segmentation
EPS
Earnings Call
Income Statement
(* All numbers are in thousands)
Balance Sheet
(* All numbers are in thousands)
Cash Flow Statement
(* All numbers are in thousands)
Analyst Estimates
(* All numbers are in thousands)
Could not create stock discussion for BLLN
